What is Class Biologically Clean?
Established in 1978, Class Biologically Clean (CBC) has carved out a distinct niche in the life sciences supply chain. The company specializes in the engineering and production of flexible film isolators and containment systems that are essential for maintaining specific pathogen-free conditions. Their product portfolio is engineered to support the rigorous requirements of immunocompromised animal research, ensuring that laboratories can operate with the highest levels of sterility and precision.
By providing customizable, high-quality infrastructure, CBC acts as a foundational partner for universities and pharmaceutical developers. Their market position is defined by a blend of legacy expertise and a modern approach to laboratory safety, making them an indispensable provider for organizations that cannot afford the risks associated with environmental contamination in sensitive research settings.
How much funding has Class Biologically Clean raised?
Class Biologically Clean has raised a total of $124K across 1 funding round:
Debt
$124K
Debt (2021): $124K with participation from PPP
Key Investors in Class Biologically Clean
PPP
Public-Private Partnership
What's next for Class Biologically Clean?
With the recent capital deployment, Class Biologically Clean is expected to accelerate its innovation pipeline, focusing on the next generation of containment technology. The company will likely prioritize the expansion of its manufacturing capabilities to meet the growing global demand for modular cleanroom solutions. Furthermore, the strategic use of these funds will likely involve enhancing their service offerings to better support the evolving needs of the gnotobiotic research community.
As the company moves into this next phase of growth, the focus will remain on scaling operations while maintaining the stringent quality standards that have defined its reputation for over four decades. Investors and industry stakeholders will be watching closely to see how CBC leverages this financial momentum to capture a larger share of the specialized laboratory equipment market.
